vance of HBV subgenotypes in the development of hepatocellular carcinoma (HCC) have shown contradictory results [6] [7] [8] . Thus, the clinical significance of different HBV subgenotypes of the same genotype remains unclear. In South Korea, a very limited study on the HBV subgenotype has been done. So far, a few studies have been reported to determine the prevalence of HBV subgenotypes and viral mutations within a specific subtype [9] [10] [11] .
Previous studies have shown that HBV core gene mutation frequency may be associated with clinical features of hepatitis and the severity of chronic liver disease, and HBV core antigen is the principle target for immune responses [12] [13] [14] . Furthermore, a mutation in the HBV core gene was reported to be involved with viral evasion from immune clearance by cellular immune response [15] . The aim of this study was to determine the prevalence of HBV subgenotypes and the spectrum of mutations in the HBV precore/core region through phylogenetic analysis and to assess the efforts that the different HBV subgenotypes and mutations exert on clinical outcomes in HBV-infected Korean patients.
A total of 133 patients with chronic HBV infection were enrolled between 2003 and 2009 from the liver clinic of the Seoul St. Mary's Hospital in South Korea. All were positive for hepatitis B surface antigen (HBsAg) for more than 6 months and seronegative for hepatitis C virus (HCV). They also had no history of drug abuse or heavy alcohol consumption and serological evidence of suggestive autoimmune hepatitis, primary biliary cirrhosis, or hemochromatosis. Patients were assigned to three groups based on their clinical stage of liver disease: (1) 49 patients were histologically confirmed chronic hepatitis (CH); (2) 43 patients were diagnosed with liver cirrhosis (LC) based on clinical, hematologic, biochemical, and ultrasound criteria, and (3) 41 patients had surgically confirmed HCC, 28 with cirrhosis and 13 without. The study protocol was reviewed and approved by the Ethics Committee at the Seoul St. Mary's Hospital and informed consent was obtained from each patient prior to the study.
Serological markers of hepatitis virus infection, such as HBsAg, anti-HBs, HBeAg, anti-HBe and anti-HCV were tested using commercially available kits (Abbott Laboratories, Chicago, Ill., USA). The viral DNA was extracted from serum using QIAamp DNA mini and blood kit (Qiagen, Valencia, Calif., USA) according to the manufacturer's protocol. HBV precore/core gene was amplified using the nested PCR method, using primers HBC1 and HBC2 for the first round and primers HBC3 and HBC4 for the second round, as described previously [16] . For the complete genome sequencing of a few samples, another nested PCR was performed to amplify overlapping fragments of the HBV genome with several primer sets, as described previously [17] .
PCR products were purified using QIAquick Gel Extraction Kit (Qiagen) according to the manufacturer's protocol, and were sequenced directly using the ABI Prism Big Dye version 3.0 kit (Applied Biosystems, Foster City, Calif., USA) on an ABI 3730XL DNA automated sequencer (Applied Biosystems). Analysis of nucleotide sequences and amino acid sequences in the precore/core of all HBV/C isolates were performed using BLAST/ Align (bl2seq) on the NCBI website and the MEGA (version 4.1) program. Nucleotide and amino acid changes in each sample were compared with the sequence of a pro- totype virus in Korea [18] . Mutations in B cell, CD4+ helper T cell, and cytotoxic T lymphocyte (CTL) epitopes of hepatitis B core antigen (HBcAg), as described separately in a previous study, were defined for each liver disease stage group [15] . Nucleotide sequences of precore/ core gene and the complete genome of HBV isolates were aligned using ClustalX (version 1.81) software and phylogenetic trees were constructed by the neighbor-joining method with other HBV reference strains from GenBank. The phylogenetic distances were calculated by bootstrapping with 1,000 repeats and molecular evolutionary analysis was performed using the MEGA (ver.4.1) program. Data were analyzed statistically using the 2 test and ANOVA, where appropriate. Multivariate analysis with logistic regression was used to determine independent factors related to the clinical development of CH, LC, and HCC. Differences between groups were compared, and p ! 0.05 was deemed to indicate statistical significance.
No significant difference was observed among the three clinical statuses with respect to sex, AST, ALT, or anti-HBs positive; however, mean age and mean HBV DNA level of CH patients were significantly younger and higher than the patients who had LC and HCC (p ! 0.01 and p ! 0.009, respectively). The rates of HBeAg positivity and anti-HBe positivity were significantly higher and lower, respectively, in patients with CH than in those with LC (p ! 0.002) ( table 1 ) .
HBV precore/core sequences of all 133 isolates were compared with those from other reference HBV strains of A-H genotypes and subgenotypes by phylogenetic analysis ( fig. 1 ). 131 isolates (98.5%) were designated as HBV subgenotype C2, whereas only CMC25B (GU827640) and CMC107L (GU721029) belonged to subgenotype 'A2' and 'C7', respectively. To confirm detection of the HBV/ C7 subgenotype, the complete genome of the isolate was sequenced. The alignment data showed that the isolated sequences corresponded most closely to that of the C7 reference strain (EU670263).
Two isolates, CMC67H and CMC91L, showed inframe deletion of identical lengths (87 bp; nt 2137-2223), which overlapped the P and core gene sequences. For comparison of nucleotide and amino acid sequences of the complete precore/core region, 129 HBV/C2 subgenotype isolates without the above 2 deleted isolates were separately analyzed by each of the disease stage group, and the genetic divergences are shown in table 2 . Nucleotide and amino acid change rates in isolates from LC patients were significantly higher (p ! 0.02) than in those from CH patients. Amino acid changes in the core gene Phylogenetic tree constructed based on the precore/core region using A2, C7, and randomly selected HBV/C2 isolates in this study and reference strains (genotypes A to H) in other phylogenetic studies. The GenBank accession numbers for the reference strains are indicated, and the isolates detected in this study are underlined (code: CMC). The alignment was analyzed by 1,000 bootstrapping replicates using the neighborhood-joining method in MEGA version 4. encoding T and B cell epitopes of HBcAg are shown in table 3 . The amino acid changes in CTL epitope (p ! 0.020), CD4+ T cell epitope (p ! 0.027), and B cell epitope (p ! 0.029) were significantly higher in LC patients than that in CH patients, but not in HCC patients.
The present study demonstrates that HBV/C2 (98%) is the predominant HBV subgenotype among chronic HBV carriers in Korea. This result is consistent with previous reports from Korea [9, 10] ; however, a novel HBV isolate, identified as HBV/C7 in the Philippines [19] , was first detected in Korea in this study. Cavinta et al. [19] suggested that the HBV/C7 strain in the Philippines could have evolved from HBV subgenotype C2 by a new genetic mechanism. However, it is unclear whether the novel HBV/C7 isolate described here also evolved from the C2 subgenotype in Korea, or if the strain was transported by the patient from the Philippines. This should be investigated further. Interestingly, only 1 patient of 133 with chronic HBV infection had HBV genotype A2 which is known to be a very rare strain in Korea. In this study, subgenotyping was performed solely by sequencing and phylogenetic analysis of the precore/core gene. Indeed, recent studies have demonstrated that sequence analysis of the entire precore/core region produces consistent HBV genotyping data compared with the results of P gene, S gene, X gene, or even complete genome of HBV [3, 16, 20] .
It is generally assumed that the genotype or subgenotype to which a viral isolate belongs could be related to the virulence and pathogenesis in patients infected with the particular virus. Genotype C HBV has been reported to be more prevalent in patients with advanced liver diseases such as LC or liver fibrosis, and this genotype was closely associated with more severe clinical outcomes and worse prognosis during antiviral therapy compared with genotype B HBV [5, 21, 22] . However, the comparison of clinical outcomes between genotypes or subgenotypes in Korea was difficult because HBV genotype C comprised almost 100% of total HBV infections [23] . This finding may be attributable to the homologous ethnic background of the Korean population.
In the present study, mean age was significantly younger but the rate of HBeAg positivity was significantly higher in the CH group than the LC or HCC group. These results are consistent with previous results from Japan and China [3, 24, 25] . These finding might be explained that the age of the CH patients infected with HBV was relatively younger than those who were LC patients. Broadly, there are four phases in the evolution of chronic HBV infection: (1) the immune tolerant phase; (2) the immune clearance phase; (3) the low replicative phase, and (4) the reactivation phase. During the low replicative phase, active replication of HBV ceases and then HBeAg becomes negative. In the past, most investigations have focused on analysis of the genetic variation of the basal core promoter and/or precore regions rather than on the core gene. The pathogenic role of core promoter (CP) mutations (T1762/ A1764) of HBV in disease progression has reported, and double CP mutations at baseline were significantly associated with the eventual development of cirrhosis or HCC [23] . However, it was assumed that the variation of the core gene or structural change of HBcAg may be more associated with the severity or progression of liver disease because HBcAg is a critical target for CTL response [15] . It was therefore suggested that the core gene mutation can alter CTL activity; this may be clinically significant, because these cells have a major role in the clearance of HBV-infected hepatocytes and are known to mediate liver damage [26] . In this study, the genetic divergence of nucleotides and amino acids in the core gene of HBV from individuals with LC was significantly higher (p ! 0.02) than in those from patients with CH group. Furthermore, rates of amino acid change in CTL epitope, CD4+ T cell epitope, or B cell epitope of HBcAg of HBV/C isolates were significantly higher in advanced liver diseases (e.g. LC) than in those in the CH group, suggesting that mutations in these immune eitopes in the core gene may be related to chronic disease progression. However, no significance was observed in these changes of immune epitopes of the core gene between the CH and HCC groups. This may explain why some patients with HCC have no evidence of liver cirrhosis which is required over a long period of time. Thus, these findings suggest that due to implications for clinical progression and disease severity, continuous surveillance for genetic variation of HBV core region may be valuable.
